par Van Cutsem, Eric;Vervenne, Walter L;Bennouna, Jaafar;Humblet, Yves;Gill, Sharlene;Van Laethem, Jean-Luc ;Verslype, Chris;Scheithauer, Werner;Shang, Aijing;Cosaert, Jan;Moore, Malcolm J
Référence Journal of clinical oncology, 27, 13, page (2231-2237)
Publication Publié, 2009-05
Référence Journal of clinical oncology, 27, 13, page (2231-2237)
Publication Publié, 2009-05
Article révisé par les pairs
Résumé : | Treatment with gemcitabine provides modest benefits in patients with metastatic pancreatic cancer. The addition of erlotinib to gemcitabine shows a small but significant improvement in overall survival (OS) versus gemcitabine alone. Phase II results for bevacizumab plus gemcitabine provided the rationale for a phase III trial of gemcitabine-erlotinib plus bevacizumab or placebo. |